According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

Orphan Medicines, led by the gene therapy Zolgensma and the Cystic Fibrosis treatment Trikafta were the most successful launches according to IQVIA list price sales data in Europe in 2020 (figure 2).

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...

Sales are expected to surpass that total in 2024. Like Vertex’s top-selling drug Trikafta, Alyftrek is a three-drug combination that uses a compound called tezacaftor as its chemical backbone. The two ...